Comparison of immunogenicity in Balb/C mice of commercially available recombinant hepatitis B vaccines in Iran

Journal of Medical Sciences

Volumn 8, Issue 4, 2008, Pages 415-419

  Mahboubi, Arash ^a   Shooshtari, Tahereh Hallaj ^a   Fazeli, Mohammad Reza ^a   Dinarvand, Rasoul ^a   Samadi, Nasrin ^a   Sharifzadeh, Mohammad ^b   Ilka, Houshmand ^c   Azadi, Saeed ^d   Valadkhani, Mahboubeh ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Zist Daru Danesh Ltd   (Iran)

^d Biotechnology Department   (Iran)

^e MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

Balb C mice; Commercially available; Hepatitis B vaccine; Immunogenicity

Indexed keywords

HEBERBIOVAC HB; HEPATITIS B SURFACE ANTIBODY; HEPAVAX GENE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENCY; FEMALE; HEPATITIS B; IMMUNOGENICITY; IRAN; MOUSE; NONHUMAN; POSTMARKETING SURVEILLANCE; SEROCONVERSION; VACCINATION; VIRUS IMMUNITY;

EID: 61449107920     PISSN: 16824474     EISSN: 18125727     Source Type: Journal    
DOI: 10.3923/jms.2008.415.419     Document Type: Article

References (18)

1. Ascherio, A., S.M. Zhang, M.A. Hernan, M.J. Olek, P.M. Coplan, K. Brodovicz and A.M. Walker, 2001. Hepatitis B vaccination and the risk of multiple sclerosis. N. Engl. J. Med., 344: 327-332.
2. Averhoff, F., F. Mahoney, P. Coleman, G. Schatz, E. Hurwitz and H. Margolis, 1998. Immunogenicity of hepatitis B vaccines: Implications for persons at occupational risk of hepatitis B virus infection. Am. J. Preventive. Med., 15: 1-8.
3. British Pharmacopoeia, 2007. Immunological Products. The Stationery Office. London, Appendix XIV.
4. Gow, P.J. and D. Mutimer, 2001. Treatment of chronic hepatitis. BMJ., 323: 1164-1167.
5. Guidotti, L.G. and F.V. Chisari, 2006. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol., 1: 23-61.
6. Halperin, S.A., S. Dobson, S. McNeil, J.M. Langley and B. Smith et al., 2006. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine, 24: 20-26.
7. Kane, M.A., 1998. Status of hepatitis B immunization programmes in 1998. Vaccine, 16: S104-S108.
8. Leroux-Roels, G., B. Abraham, M. Fourneau, N. Clercq and A. Safary, 2000. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents. Vaccme, 19: 937-942.
9. Otaǧ, F., 2003. False positive HBsAg result in blood donors due to administration of three different recombinant DNA Hepatitis B vaccines. Vaccine, 21: 3734-3737.
10. Rebedea, I., I.G. Diaconescu, D. Bach, O. Bartelsen and N. Arndtz, 2006. Comparison of thiomersal-free and thiomersal-containing formulation of a recombinant hepatitis B vaccine (Hepavax-Gene®) in healthy adults. Vaccine, 24: 5320-5326.
11. Safary, A. and F. Andre, 1999. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine, 18: 57-67.
12. Shokrgozar, M.A. and F. Shokri, 2002. Subtype specificity of anti-HBs antibodies produced by human B-cell lines isolated from normal individuals vaccinated with recombinant hepatitis B vaccine. Vaccine, 20: 2215-2220.
13. Thursz, M.R., D. Kwiatkowski, C.E. Allsopp, B.M. Greenwood, H.C. Thomas and A.V. Hill, 1995. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N. Engl. J. Med., 332: 1065-1069.
14. West, D.J. and G.B. Calandra, 1996. Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination. Vaccme, 14: 1019-1027.
15. Williams, I.T., S.T. Goldstein, J. Tufa, S. Tauillii, H.S. Margolis and F.J. Mahoney, 2003. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Ped. Infect. Dis. J., 22: 157-163.
16. Wood, R.C., K.L. MacDonald, K.E. White, C.W. Hedberg, M. Hanson and M.T. Osterholm, 1993. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA., 270: 2935-2939.
17. Yuen, M.F., W.L. Lim, C.C. Cheng, S.K. Lam and C.L. Lai, 1999. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology, 29: 924-927.
18. Zinkernagel, R.M., S. Ehi, P. Aichele, S. Oehen, T. Kundig and H. Hegartner, 1997. Antigen localization regulates immune response in a dose- and time-dependent fashion: A geographical view of immune reactivity. Immunol. Rev., 156: 199-209.